Ohio cancer center breaks ground on $1 billion addition

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 8
Volume 19
Issue 8

The Ohio State University Comprehensive Cancer Center–Authur G. James Cancer Hospital and Richard J. Solove Research Institution (OSUCCC-James) has begun construction on a 276-bed cancer facility.

The Ohio State University Comprehensive Cancer Center-Authur G. James Cancer Hospital and Richard J. Solove Research Institution (OSUCCC-James) has begun construction on a 276-bed cancer facility.

Entitled ProjectONE, the Columbus-based facility will allow the center to keep up with a projected 21% growth in admission during the next decade, according to cancer center administrators. The new hospital will serve as a research center,with 10,000 full-time jobs generated. Visit projectone.osu.edu/ for more information.

Based on community feedback, OSU Medical Center CEO Steven Gabbe, MD, announced revisions to the original ProjectONE design in June 2010.

"As with building a house, the best plans often need refining as planning and construction progress," Dr. Gabbe said. "The new model calls for four neighborhoods, each with its own tower. The neighborhoods include three areas with 12-bed patient units and a fourth for education and clinical research. Rooftop gardens accessible to patients and their families have been added as well."

OSUCC-James is slated to open a 103,000-square foot Women's Breast Center in January 2011.

In addition, the James Cancer Hospital will add several dozen new beds to accommodate new surgical, breast cancer, leukemia, and lymphoma patients.

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.